Chong Kun Dang, Jinyang increase their collaboration for new premature ejaculation drug

Published: 2013-05-31 06:56:00

Updated: 2013-05-31 06:56:00

Chong Kun Dang Pharmaceutical and Jinyang Pharmaceutical announced Monday that both companies has signed an agreement to extend their collaboration for Jinyang’s new premature ejaculation treatment containing clomipramine.

Under the contract, Jinyang officials said that Chong Kun Dang will exc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK